AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alanine--tRNA ligase, cytoplasmic

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P49588

UPID:

SYAC_HUMAN

Alternative names:

Alanyl-tRNA synthetase; Renal carcinoma antigen NY-REN-42

Alternative UPACC:

P49588; A6NF14; B4DR45; Q53GV7; Q96FA0

Background:

Alanine--tRNA ligase, cytoplasmic, also known as Alanyl-tRNA synthetase and Renal carcinoma antigen NY-REN-42, plays a crucial role in protein synthesis. It catalyzes the attachment of alanine to tRNA(Ala), a fundamental process for translating genetic information into functional proteins. This enzyme not only activates alanine but also ensures accuracy through its editing domain, preventing mischarged tRNA(Ala) from disrupting protein synthesis.

Therapeutic significance:

The enzyme's association with diseases such as Charcot-Marie-Tooth disease, axonal, 2N, Developmental and epileptic encephalopathy 29, Leukoencephalopathy, hereditary diffuse, with spheroids 2, and Trichothiodystrophy 8, non-photosensitive, highlights its potential as a target for therapeutic intervention. Understanding the role of Alanine--tRNA ligase, cytoplasmic could open doors to potential therapeutic strategies, offering hope for patients suffering from these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.